88% of over-16s in the UK have received one dose of vaccine
GSK (LON:GSK), along with a South Korean pharmaceutical company, have begun a third phase trial of their Covid-19 vaccine combination.
The FTSE 100 company made the announcement on Tuesday that the news came on the back of “positive” interim results during the Phase 1 and 2 studies.
The two firms are now aiming for global supply through the Covax facility in the first six months of 2022, subject to data and regulatory reviews.
Levels of antibodies that neutralise the virus were between five and eight times higher in vaccinated candidates than in people who had previously been infected with Covid-19.
Thomas Breuer, Chief Global Health Officer, GSK said that “while many countries have made good progress with vaccination, there remains a need for accessible and affordable COVID-19 vaccines to ensure equitable access and to protect people across the world”.
Recent figures show that around 88% of over-16s in the UK have received at least one vaccine dose.
“We are pleased to contribute with GSK’s pandemic adjuvant and to be working with SK to deliver the vaccine at scale via COVAX if it is approved,” he added.
The late-stage trial will involve around 4,000 participants from a variety of countries to assess the vaccine candidate’s safety and immunogenicity compared with the Oxford AstraZeneca vaccine.
The GSK share price is down by 1.18% during the morning session on Tuesday.
, along with a South Korean pharmaceutical company, have begun a third phase trial of their Covid-19 vaccine combination.){kind=link}